Atlas Venture targets $450M for 14th biotech fund, the same size as its 2022 raise
Atlas Venture, one of biotech’s go-to VC firms, is eyeing a $450 million 14th fund, partner Bruce Booth said in its annual review presentation. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
